Oral Encochleated Amphotericin B (CAMB)
MB-70006
Phase 2 small_molecule terminated
Quick answer
Oral Encochleated Amphotericin B (CAMB) for Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at Matinas BioPharma Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Matinas BioPharma Holdings
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated